

CURRICULUM VITAE

Harinderjit Singh, M.D.

3699 Inverness Way
Augusta, GA 30907
(O) 706-396-5700 (C) 706-284-4301 (F) 706-396-5701
(E) hsingh@singhinvestment.com

INSTITUTIONAL AFFILIATIONS

Clinical Associate Professor of Ophthalmology, Medical College of Georgia. Retired

EDUCATION

| | | |
|--|-------------|-----------|
| *Botany, Zoology, Chemistry Higher Secondary School, Sector 7, Bhilai (M.P.) India | High School | 1965 |
| *St. Xavier's College, Ranchi, India | B.S.C. | 1965-1968 |
| *Gandhi Medical College, Bhopal, India | M.B.B.S | 1968-1973 |
| *Rotating Intern, General Hospital, Bhilai, India | | 1973-1974 |
| *Resident in Nephrology, University Hospital, The University of Western Ontario, London, Ontario, Canada | | 1974-1975 |
| *Straight Intern in Medicine. The University of Western Ontario Hospitals London, Ontario, Canada | | 1975-1976 |
| *Rotating Intern, Reddy Memorial Hospital, McGill University Teaching Hospital, Montreal, Quebec, Canada | | 1976-1977 |
| *Resident in Ophthalmology. The University of Western Ontario Hospitals London, Ontario, Canada | | 1977-1980 |
| *Fellow in Diseases of the Retina and Vitreous, Retina Consultants, Ltd., Barnes Hospital, Washington University, St. Louis, Missouri | | 1980-1981 |

MERITS AND AWARDS.

- Final BSc from Ranchi University: 9th in Merit list of Ranchi University
- First MBBS exam Vikram University: 8th in Merit List.
- Final MBBS exam, Bhopal University: 7th in Merit List.
- Awarded best teacher for Residents. Dept. of Ophthalmology, Medical College of Georgia, Augusta, GA in 1994-95.
- Best Doctors Award every year from 1999 to 2017.
- Top Ophthalmologist of US from 2014 to 2017

PROFESSIONAL

*Instructor in Anatomy, University of Western Ontario, London, Ontario, Canada 1974-1975

*Associate Clinical Professor of Ophthalmology, Medical College of Georgia, 1988-2017
Augusta, Georgia

PRACTICE EXPERIENCE

1982-1983 Solo Practice, Saskatchewan, Canada
Specializing in Disease and Surgery of the Retina and Vitreous

1983-1984 Group Practice, Odessa, Texas
Specializing in Diseases and Surgery of the Retina and Vitreous

1984- 2017 Group Practice- Southeast Retina Center, P.C., Augusta, Georgia
Specializing in Diseases and Surgery of the Retina and Vitreous –
Partner/Surgeon. I started this practice in 1984 and retired from this practice in
2017. In 1999 I also started a free standing Retina only outpatient Surgical center
adjoining the office.
2020 Jan to present: working Part-time at Augusta VA

CURRENT ACTIVE MEDICAL LICENSES:

GEORGIA 26652
TEXAS G4404
NEW YORK 145017-1
DEA FS 7706837 (REGISTERED FOR TEXAS)

SCIENTIFIC AND PROFESSIONAL SOCIETIES

Member of Canadian Ophthalmology Society
Member of American Academy of Ophthalmology-1982
Fellow of the Royal College of Physicians and Surgeons (Canada)
Member of the All India Ophthalmology Society
Member of the American Society of Retina Specialist
Member of Canadian Society of Retina.
Member of the Paul Cibis Club

MEETINGS, VISITING PROFESSORSHIPS

- * Indocyanine Green Angiography, University of South Carolina, Columbia, South Carolina
- * Amritsar Ophthalmology Society, Keynote Speaker, December 2009
- * Department of Ophthalmology, PGI, Chandigarh, India
- * Grewal Eye Institute, Chandigarh, India
- * Gandhi Medical College, Bhopal, India
- * All India Ophthalmological Society
- * Vitreo-Retina Society of India
- * Punjab Ophthalmological Society, Punjab, India

CO-INVESTIGATOR IN THE FOLLOWING CLINICAL TRIALS:

- 2000 Novartis: Phase III of Visudyne treatment with classic choroidal neovascular membrane
- 2001 Genentech, Inc.: Anti-VEGF Monoclonal antibody Fragment (rhuFab V2)
- 2003 Eli Lilly and Company, Protocol B7A-MC-MBDL: Reduction in the Occurrence of Center-Threatening Diabetic Macular Edema.
- 2003 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema.
- 2003 Genentech: Phase III, Placebo-Controlled, Multi-Center Study to Examine the Safety and Efficacy of Multiple-Dose Intravitreal Injections of the rhuFab V2 in Subjects with Age-Related Macular Degeneration Who Have Predominant Classic Lesion Degeneration.
- 2004 Alcon, Inc. and Bayer, Inc.: Determination of Intravitreal and Aqueous Concentrations of Moxifloxacin after Oral Administration in Scheduled Vitrectomy Patients.
- 2004 Novartis/QLT Inc.: A Randomized, Placebo-Controlled, Double Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Minimally Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Minimally Classic (VMC).
- 2004 EyeTech Pharmaceuticals, Anti-VEGF Pegylated Aptamer (EYE001): Intravitreal Injections for Exudative ARMD- Phase II/III Trial.
- 2004 Boehringer Ingelheim Pharmaceuticals, Inc.: A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients (Mirapex study).
- 2004 Family Investigation of Nephropathy and Diabetes, The FIND Eye Study: Identifying Genes Responsible for Diabetic Nephropathy and their Linkage Relationships to Nephropathy (FIND).
- 2005 Genaera MSI-1256F-301/302: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lacate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.
- 2005 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: A Randomized Trail Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema (Protocol B).
- 2005 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin). (Protocol H)

- 2005 EyeTech Pharmaceuticals, Inc.- A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of 0.3, 0.03 or 0.003 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula.
- 2005 Lilly Research Laboratories, Protocol B7A-MC-MBDL: Reduction in the Occurrence of Center-Threatening Diabetic Macular Edema
- 2005 Regeneron VGFT-OD-0508: A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration.
- 2005 Genentech, Inc. FVF3689g: A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (SAILOR Study).
- 2005 Schering-Plough Corporation: Determination of Intravitreal Concentrations after Oral Administration of Moxifloxacin in Scheduled Vitrectomy Patients.
- 2006 Genentech, Inc. FVF3761s: Treatment of Polypoidal Choroidal Vasculopathy with Ranibizumab (Lucentis): A Phase I/II Safety Study (Poly Study).
- 2005 Jaeb Center for Health Research, National Eye Institute: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to treat Macular Edema Associated with Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion (SCORE Study).
- 2006 Alimera C-01-05-001: A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5mg/day and ASI-001B 0.2mg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema (FAME).
- 2006 EyeTech Pharmaceuticals, Inc. Protocol EOP1023: A Phase IV, Open Label, Multi-Center, Trial of Maintenance Intravitreal Injections of Macugen® (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated with a Modality Resulting in Maculopathy Improvement (Level Study).
- 2007 Regeneron VGFT-OD-0702: An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration (Extension of Regeneron protocol 0508).

- 2007 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema (Protocol I).
- 2007 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative and Non-Proliferative Diabetic Retinopathy (Protocol J).
- 2007 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: The Course of Response to Focal Photocoagulation for Diabetic Macular Edema (Protocol K).
- 2007 Genentech, Inc. FVF4165g: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (Bravo Study).
- 2007 Genentech, Inc. FVF4166g: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (Cruise Study).
- 2007 Genentech, Inc. FVF4168g: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (Ride Study).
- 2007 Eli Lilly and Company, Protocol B7A-MC-MBCU: The Effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography (MBCU Study).
- 2007 Opko Health, Inc. Protocol ACU301C: A Phase 3, Randomized, Double-masked, Parallel-Assignment study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis®, Compared with Lucentis® Monotherapy Every 4 Weeks in Patients with Exudative Age-Related Macular Degeneration (AMD) (Cobalt Study).
- 2007 Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-0605: A Randomized, Double-masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (View 1 Study).
- 2007 RegenRx Biopharmaceuticals, Inc. Protocol RGN-DV-201: A Randomized, Double-Mask, Placebo-Controlled, Dose-Response, Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Diabetic Patients' Corneal Wounds Resulting from Epithelial Debridement During Vitrectomy.

- 2008 Allergan, Protocol 206207-012: A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-Up) to Assess the Safety and Efficacy of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Macular Edema (DME).
- 2008 Neovista, Protocol NVI-114-08: A Randomized, Prospective, Active Controlled, Study of the Epi-Rad Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (Cabernet).
- 2008 Pfizer. A Phase II, Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose-Ranging, Comparator Study Evaluating the Efficacy and Safety of PF-04523655 versus Laser Therapy (DEGAS).
- 2008 Ophthotech: A Phase I, Ascending Dose and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Multiple Intravitreal Injections of Volociximab ($\alpha 5\beta 1$ Integrin Antagonist) as Monotherapy or in Combinations with Lucentis 0.5 mg/eye in Subjects with Neovascular Age-Related macular Degeneration.
- 2008 Genentech FVF3426g: An Open Label, Multi-Center Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Edema Secondary or Retinal Vein Occlusion (RVO) who have Completed a Genentech Sponsored Ranibizumab Study (Horizon).
- 2009 Thrombogenics: A Randomized, Placebo Controlled, Double-Masked, Multi-Center Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.
- 2009 Genentech FVF4579g: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or On An As-Needed Basis (PRN) In Patients with Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR Study).
- 2009 Regeneron Pharmaceuticals, VGFT-OD-0706: A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema.
- 2009 Regeneron Pharmaceuticals, VGFT-OD-0819: A Randomized, Double masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.
- 2009 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema (Protocol O).

- 2009 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: A Pilot Study in Individuals with Center-Involved Diabetic Macular Edema Undergoing Cataract Surgery (Protocol P).
- 2009 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery (Protocol Q).
- 2009 Pfizer, Protocol A1451259: A Non-Treatment Study of Risk Factors for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).
- 2010 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (Protocol N).
- 2010 Pfizer, Protocol B1181002: A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G In Subjects With advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy.
- 2010 Juvenile Diabetes Research Foundation: Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 with High Dose- the Read 3 Study.
- 2010 The Macula Foundation with Genentech, Inc., Protocol FVF4926s: Extended Follow-up of Patients with Macular Edema due to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) previously treated with Intravitreal Ranibizumab (Retain).
- 2010 Regeneron Pharmaceuticals, VGFT-OD-0910: An Open-Label, Long-Term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (View 1 Extension).
- 2011 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: A Phase II Evaluation of Topical NSAIDs in Eyes with Non-Central Involved DME (Protocol R).
- 2011 Genentech, Inc., Protocol FVF4967g: A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion (SHORE).
- 2011 Santen, Inc., Protocol 32-007: A Phase III, Multinational, Multicenter, Randomized, Double-Masked Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infections Uveitis of the Posterior Segment of the Eye (Sakura).
- 2011 Regeneron Pharmaceuticals, Protocol VGFT-OD-1009: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (Vista).

- 2011 Genentech, Inc., Protocol CFD4870g: A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy (Mahalo).
- 2011 Alimera, Protocol C-01-11-008: An Open-label, Multi-center Extension Study of the Safety and Utility of the New Inserter of Iluvien (fluocinolone acetonide intravitreal insert) 0.19mg in Subjects and the Safety of Iluvien in Subjects with Macular Edema (FAME Extension).
- 2011 Genentech, Inc., Protocol FVF4916s: Treatment of Polypoidal Choroidal Vasculopathy with High Dose Ranibizumab (Lucentis): A Phase I Safety Study (High Tide Poly).
- 2011 Lpath, Inc., Protocol LT1009-Oph-003: A Phase 2A, Multi-center, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP (Sonepcizumab [LT1009]) as either Monotherapy or Adjunctive Therapy to Lucentis of Avastin Alone for the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
- 2012 Acucela Inc., Protocol 4429-202: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry-Age-Related Macular Degeneration.
- 2012 Alcon Research Ltd., Protocol C-12-006: A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 versus EYLEA in Subjects with Exudative Age-Related Macular Degeneration (OSPREY).
- 2012 Genentech, Protocol GX28198: A Multicenter, Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of FCFD4514S in Patients with Geographic Atrophy (OLEi).
- 2012 Genentech, Protocol ML28713: Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial).
- 2012 GlaxoSmithKline, Protocol BAM114341: A Phase 2, Multi-centre, Randomised, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
- 2012 Jaeb Center for Health Research: A Validation Study of the Electronic – ETDRS Test Protocol for Low-Contrast Visual Acuity Testing in Adults and Older Children (EVA Low-Contrast VA)
- 2012 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (Protocol T).

- 2012 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S).
- 2012 Pfizer: Protocol B1181003: A Phase 2 Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multidose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
- 2012 QDR, Protocol 2010-00703 DME: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the Foveal Center (iDeal).
- 2012 Regeneron: Intravitreal Aflibercept Injection for the treatment of CHoroidal Neovascularization secondAry to presumed ocuLar histoplasmosis syndromE (the HANDLE study). Principal Investigator.
- 2012 Regeneron, Protocol VGFTe-AMD-1124: An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration (RE-VIEW).
- 2012 Regeneron: Protocol VGFTe-RVO-1027: A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety and tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (Vibrant).
- 2012 Quark Pharmaceuticals, Protocol QRK202: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined with a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (Matisse).
- 2013 Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (Protocol V).
- 2013 Pfizer, Protocol B1261009: A Phase 2 Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study to Compare the Efficacy and Safety of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) with that of Ranibizumab in Adult Subjects with Diabetic Macular Edema.
- 2013 Ophthotech, Protocol OPH1003: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista™ (Anti PDFT-B Pegylated Aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.

- 2013 Regeneron: Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-Related Macular Degeneration Extension Study (0910) RANGE.
- 2014 Jaeb Center for Health, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (Protocol U).
- 2014 Regeneron- Investigator Initiated Study: Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL TRIAL).
- 2014 National Eye Institute: Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2).
- 2014- ThromboGenics: Ocriplasmin Research to Better Inform Treatment (ORBIT): A Phase IV Observational Study.
- 2014- Genentech: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of 10 mg Lampalizumab Intravitreal Injections Administered Every 30 or 45 Days to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA).
- 2014- Allergan: Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema.

- 2015- Ophthotech, Protocol OPH1005, Sub-Retinal Fibrosis in Neovascular AMD: A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regimen Administered in Combination with Anti-VEGF Therapy (Avastin® or Eylea®) During the Induction and Maintenance Phase of Therapy.
- 2015- Alimera Sciences, Iluvien® (Fluocinolone Acetonide Intravitreal Implant) M-01-15-004, A Phase 4 Safety Study of IOP Signals in Patients Treated with Iluvien® 0.19 MG (PALADIN).
- 2015-2016 A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age Related Macular Degeneration (EMERGE).
- 2015- 2016 Alcon Research, Ltd., Protocol RTH258-C001, Efficacy and Safety of RTH258 versus Aflibercept: A Two-Year, Randomized, Double-Masked, Multicenter, Three – Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age Related Macular Degeneration (HAWK).
- 2015- Ophthotech, Protocol OPH1006, Effect of Anti-VEGF Agents Administered on a Quarterly Maintenance Regimen in Subjects with Neovascular AMD Receiving Anti-PDGF Therapy: An 18 Month Phase 2A Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination with Fovista (Anti-PDGF BB Pegylated Aptamer).
- 2015- Allegro, Protocol DME 202B, A Phase 2 Multicenter, Randomized, Controlled, Double Masked Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminata (Alg-1001) As Compared to Avastin And Focal Laser Photocoagulation in The Treatment of Diabetic Macular Edema.
- 2015- Regeneron Pharmaceuticals, Protocol R2176-3-AMD-1417, A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 In Patients with Neovascular Age-Related Macular Degeneration (CAPELLA).
- 2015- Genentech, Inc., Protocol GX28228, A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of The Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (LADDER).
- 2015- Roche, A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AVENUE).

- 2015- Tyrogenex, Protocol X82-OPH-201, A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-inferiority Study of X-82 Plus Prn Eylea Compared to prn Eylea Monotherapy in Neovascular AMD.
- 2015- Regeneron Pharmaceuticals, Investigator Initiated Research Grant, Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab (ROTATED).
- 2016- Apellis Pharmaceuticals, A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA). (FILLY).
- 2016- Regeneron Pharmaceuticals, A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (PANORAMA).
- 2015-2016 Neurotech, A Multi-Center, Two-Stage, Open-Label Phase 1 and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).
- 2016- Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network, Anti-VEGF for PDR/DME Prevention Study (PROTOCOL W).
- 2016- Astellas, A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (VIDI.) Principal Investigator.
- 2016- Regeneron Pharmaceuticals, Investigator Initiated Research Grant, Endolaserless Vitrectomy with Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (LASER LESS).
- 2016- OHR Pharmaceuticals, A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration (MAKO).
- 2016- Regeneron Pharmaceuticals, A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema (RUBY).
- 2016- Regeneron Pharmaceuticals, A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (ONYX).

- 2016- Roche, A Multiple-Center, Multiple-Dose, Randomized, Active Comparator–Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (BOULEVARD).
- 2014- Roche, A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of 10 mg Lampalizumab Intravitreal Injections Administered Every 30 or 45 Days to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA).
- 2014- 2016 Thrombogenics, Ocriplasmin Research to Better Inform Treatment (ORBIT).
- 2014- 2015 Allergan, Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema (PALM).
- 2014-2015 Retina Associates of Hawaii, Intravitreal Aflibercept Injection (Eylea) for Polypoidal Choroidal Vasculopathy with Hemorrhage or Exudation (EPIC).
- 2015- Jaeb Center for Health Research, National Eye Institute, Diabetic Retinopathy Clinical Trial Network: Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawid field Fundus Images and Risk of DR Worsening Over Time (PROTOCOL AA).

ABSTRACTS/PRESENTATIONS/PUBLICATIONS

Changes in Diabetic Retinopathy Through 2 years: Secondary Analysis of Randomized clinical trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.

Susan B Bressler MD, Danni Liu MSPH; Adam Glassman; Barbara A Blodi; Alessandro A Castellarin, MD; Lee M, Jampool,MD; Paul Kaufman,MD; Michele Melia ScM; Harinderjit Singh, MD; John A. Wells MD; for DRCR network.

JAMA Ophthalmology April 2017,135(6) 558-568 .

Intravitreal Aflibercept injection (IAI) for Persistent DME after treatment with Bevacizumab and /or Ranibizumab: ROTATED Trial 52 weeks Results; By Caitlen Taylor BS; Heather Frazier, BS; Priscilla Rex; William Marcus; David Starnes,BS; Harveen Walia,MS; Evin M Samy; Harinderjit Singh, MD; Robert A LalaneIII, MD; Dennis M Marcus,MD. Presented at ARVO 2019.

Intravitreal Aflibercept for Neovascular Ployploidial Choroidal Vasculopathy in a Predominantly Non Asian Population (RIVAL Trial) Dennis M Marcus, MD; Farrooq; Frazier H; Marcus WM; Harinderjit Singh, MD; Published in Ophthalmic Surgery, laser and Imaging Retina Jan 2017 Vol 46 No 1.

**Endolaserless Vitrectomy With Intravitreal
Aflibercept Injection for Proliferative
Diabetic Retinopathy-Related Vitreous
Hemorrhage (LASER LESS TRIAL)**

Dennis M. Marcus, MD¹, Harinderjit Singh, MD¹, Davis C. Starnes, BS¹,
Harveen Walia, BS¹, Amina Farooq, MD², Heather Frazier, BS¹,
William B. Marcus¹, and Robert A. Lalane, MD
Published in Journal Of Vitreo Retinal Disease, April 2018

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage (LASER LESS TRIAL): 44 Week Results. Marcus DM, Singh, Harinderjit; Farooq, Amina; Starnes, Davis; Walia, Harveen; Frazier, Heather, Lalane, RA. Presented at the Macula Society Meeting, Beverly Hills, CA. February 2018

Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results. Marcus DM, Frazier H, Rex P, Marcus WB, Starnes D, Walia H, Singh H, Lalane RA. Investigative Ophthalmology & Visual Science June 2018, Vol.59, Abstract #3598

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage: 1 Year Results (LASER LESS TRIAL). Dennis M. Marcus, MD, Harinderjit Singh, MD, Robert A. Lalane III, MD, Southeast Retina Center, Augusta, GA. Presented at ASRS annual meeting July 2018 Vancouver, British Columbia, Canada.

**Wide-Field Fluorescein Angiographic-Guided Aflibercept (WFFAGA) Monotherapy
for Proliferative Diabetic Retinopathy (PDR)**

Lindsay Williamson, BS¹; Davis Starnes, BS¹; Caitlen Taylor, BS¹; Rachel Levy, BA¹; Venkatkrish Kasetty, BS¹; Priscila Rex¹; Harinderjit Singh, MD¹; Robert A. Lalane, MD¹; Dennis M. Marcus, MD¹
Published in Journal of Vitro retinal Disease 2019.

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy In A Predominantly Non-Asian Population (RIVAL Trial). Marcus DM, Farooq A, Frazier H, Fechter CM, Marcus WB, Singh H. To be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, Washington, May 2016.

Ranibizumab (0.3 mg) for Persistent Diabetic Macular Edema (DME) After Recent, Frequent, and Chronic Bevacizumab (ROTATE Trial). Farooq A, Frazier H, Fechter CM, Marcus WB, Singh H, Marcus DM. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, Washington, May 2016

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population. Marcus DM, Singh H, Farooq A, Frazier H, Marcus WB, Fechter C. Presented at the Retina Society Meeting, Paris, France, October, 2015.

Intravitreal Aflibercept for Presumed Ocular Histoplasmosis Syndrome (POHS)-related Choroidal Neovascularization (CNV): Results from the HANDLE Study. Marcus DM, Toussaint B, Kitchens J, Miller D, Singh H. Presented at the Macula Society Meeting, Scottsdale, AZ, February, 2015.

Ranibizumab (0.3 mg) For Persistent Diabetic Macular Edema (DME) After Recent, Frequent and Chronic Bevacizumab (ROTATE Trial): Six Month Results. Marcus DM, Singh H, Farooq A, Frazier H, Marcus WB, Fechter C. Presented at the American Society of Retina Specialists (ASRS) Meeting, Vienna, Austria, July, 2015.

Intravitreal Aflibercept for Presumed Ocular Histoplasmosis Syndrome (POHS)-related Choroidal Neovascularization (CNV): Results from the HANDLE Study. Marcus DM, Toussaint B, Kitchens J, Miller D, Singh H. Presented at the Macula Society Meeting, Scottsdale, AZ, February, 2015.

High-Dose Ranibizumab for Non-Asian Neovascular Polypoidal Choroidal Vasculopathy. Fechter C, Singh H, Chamberlain DP, Marcus DM. To be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Denver , CO, May 2015; Abstract # 234

#Evaluation of Rescue Treatment with Intravitreal Aflibercept Injection (IAI) in Patients with Diabetic Macular Edema (DME) Randomized to Laser in the VISTA and VIVID Studies. Marcus DM. To be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Denver , CO, May 2015; Abstract # 2155669

Long-term Follow-up of Intravitreal Aflibercept Injection (IAI) for Neovascular Age-Related Macular Degeneration (nAMD) in an Open-Label Extension of the VIEW 1 Study. Toussaint B, Marcus DM, Miller D, Kitchens JW, Singh H, Foster R, Petersen MR, Sisk R, Riemann C. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL, May 2014, Invest Ophthalmol Vis Sci. 2014;54(suppl.): Abstract # 3943.

Intravitreal Aflibercept for Presumed Ocular Histoplasmosis Syndrome (POHS)-related Choroidal Neovascularization (CNV): Short-term Results from the HANDLE Study. Toussaint B, Marcus DM, Miller D, Kitchens JW, Singh H, Foster R, Petersen MR, Sisk R, Riemann C. Presented as

online presentation at the Annual Meeting of the Macula Society, Key Largo, FL, February, 2014; presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL, May 2014, Invest Ophthalmol Vis Sci. 2014;54(suppl.):Abstract # 3923.

Intravitreal Ranibizumab for Non-Asian Polypoidal Choroidal Vasculopathy. Marcus DM, Singh H, Lott MN, Singh J. Marcus M. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2010, Invest. Ophthalmol. Vis. Sci. 2010;51(suppl.):Abstract # 2229 and at the Annual Meeting of the American Society of Retinal Specialists, Vancouver, BC, August 2010.

Current Treatments for Age Related Macular Degeneration. Presented at the Annual Meeting of Punjab Ophthalmological Society, Amristar, India, December 18, 2009.

Current Treatments for Diabetic Macular Edema. Presented at the Annual Meeting of Punjab Ophthalmological Society, Amristar, India, December 18, 2009.

Anterior Ischemic Optic Neuropathy. Presented at the Annual Meeting of Punjab Ophthalmological Society, Amristar, India, December 18, 2009.

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy. Lott MN, Singh J, Singh H, Marcus DM. Presented at the American Academy of Ophthalmologist, San Francisco, CA, October, 2009.

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy. Lott MN, Singh J, Singh H, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2009, Invest. Ophthalmol. Vis. Sci. 2009;50(suppl): Abstract #6200.

Intravitreal Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy. Baumrind BR, Singh H, Lott MN, Singh J, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, April/May 2008, Invest. Ophthalmology. Vis. Sci. 2008;49 (suppl.):Abstract #299.

Treatment of Polypoidal Choroidal Vasculopathy with Ranibizumab (Lucentis): A Phase I/II Safety Study. Marcus DM, Lott MN, Singh J, Singh H. Presented at the Retina Society Meeting, Boston, MA, September, 2007 and at the Annual Meeting of the American Academy of Ophthalmology, New Orleans, Louisiana, November, 2007.

Treatment of Polypoidal Choroidal Vasculopathy with Ranibizumab (Lucentis): A Phase I/II Safety Study. Lott MN, Singh J, Singh H, Bartoli M, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2007, Invest. Ophthalmol. Vis. Sci. 2007;48 (suppl.):Abstract #1439.

Vitreous Penetration of Oral Moxifloxacin in Humans. Singh J, Lott M, Singh H, Fuller J, Hancock H, McGwin G, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2007, Invest. Ophthalmol. Vis. Sci. 2007;48 (suppl.):Abstract #698.

23-Gauge Vitrectomy in 100 Eyes: Visual Outcomes and Complications. Manning M, Marcus DM, Singh J, Singh H. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2007, Invest. Ophthalmol. Vis. Sci. 2007;48 (suppl.):Abstract #2238.

23-Gauge Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications. Singh H, Manning M, Singh J, Marcus DM. Presented at the American Society of Retina Specialists (ASRS) Meeting, Cannes, France, September 2006 and at the American Academy of Ophthalmology Meeting, November, 2006, Las Vegas, NV.

Vitreous Penetration of Topical, Oral and Combined Dosing of Moxifloxacin in Humans. Fuller M, Lott MN, Bhaati AA, Henson, NM, Curtis MA, Singh H, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2006, Invest. Ophthalmol. Vis. Sci. 2006;47(suppl.): Abstract #5291.

ARMD new treatments and 23g Vitrectomy. Presented at the Vitreoretinal Society of India Annual Meeting, Ooty, Tamil Nadu, December 2005.

Vitreous Penetration of Topical, Oral and Combined Dosing of Moxifloxacin in Humans. Fuller J, Lott MN, Bhaati AA, Henson NM, Curtis MA, Singh H, Marcus DM. Presented at the American Academy of Ophthalmology Meeting, Chicago, IL, October, 2005.

Vitreous Penetration of Orally Administered Moxifloxacin in Humans. Marcus DM, Fuller JJ, Singh H. Presented at the American Society of Retina Specialist Meeting, Montreal, Canada, July 15, 2005.

Vitreous Penetration of Topical, Oral and Combined Dosing of Moxifloxacin in Humans. Lott MN, Fuller JJ, Robertson SM, Curtis MA, Dahlin DC, Singh H, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2005, Invest. Ophthalmol. Vis. Sci. 2005;46(suppl.): Abstract #4896.

Semantic Change Understanding of Vascular and Non-vascular Changes from Multi-Temporal Color Retinal Fundus Images. Narasimha-Iyer H, Can A, Roysam B, Stewart CV, Tanenbaum HL, Majerovics A, Singh H. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2005.

Surgical Removal of Extensive Peripapillary Choroidal Neovascularization in Elderly Patients. Bains HS, Patel MR, Singh H, Marcus DM. Presented at the Annual Meeting of the Association for Research in Ophthalmology, Ft. Lauderdale, Florida, May 2001 and the resident Alumni Meeting, Department of Ophthalmology, Medical College of Georgia, March 23, 2001. Invest. Ophthalmol. Vis. Sci. 2001;42(suppl):Abstract # 2315.

Update on Endophthalmitis. Asian Pacific Academy of Ophthalmology, Kathmadu, Nepal, India March 1997.

Keynote Speaker addressing Retinal Angiomas, Macular Hole Surgery, and Submacular Surgery. Presented at the Annual All Indian Ophthalmology Society Meeting, Delhi, India, February 1997.

Keynote Speaker addressing Sub-macular Surgery, Endophthalmitis Update and Indocyanine Green Angiography. Presented at the Indian Academy of Ophthalmology, Bombay, India, November 1996.

Digital Fluorescein Angiography. Presented at the Ophthalmology Congress, Rome, Italy, October, 1987.

Endogenous Coccidioidomycosis Endophthalmitis. Presented at the Paul Cibis Club, Interlaken, Switzerland, June, 1985.

Treatment of Blood Induced Glaucoma by Trans Pars Plana Vitrectomy; Presented at the Paul Cibis Club, Hot Springs, Virginia, May 1981.

Presumed Candida Retinitis: A Report of Six Cases. Presented at the Canadian Ophthalmological Society Conference, Vancouver, B.C., June, 1980.

PUBLICATIONS IN REFERRED JOURNALS

Diabetic Retinopathy Clinical Research Network Writing Committee (Harinderjit Singh- Participating Clinical Investigator). Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. *JAMA Ophthalmol.* 2014 Sep 1;132(9):1113-22.

Diabetic Retinopathy Clinical Research Network Writing Committee (Harinderjit Singh- Participating Clinical Investigator). An exploratory analysis of persistent macular thickening following intravitreal ranibizumab for center-involved diabetic macular edema with vision impairment. 2014 Jul. (Submitted to *JAMA Ophthalmology*).

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (Harinderjit Singh- Participating Clinical Investigator). Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. *Ophthalmology.* 2014 Jul;121(7):1414-20.e1.

Bhavsar AR, Torres K, Glassman AR, Jampol LM, Kinyoun JL; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). One year results evaluation following short term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. *JAMA Ophthalmol.* 2014 Jul;132(7):889-90.

Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus DM, Halperin L, Sadiq MA, Rajagopalan N, Campochiaro PA, Nguyen QD for the READ-3 Study Group (Harinderjit Singh- Participating Clinical Investigator). High dose ranibizumab for diabetic macular edema: month-6 primary outcomes of the READ-3 Study (Ranibizumab for Edema of the macula in Dibetes – Protocol 3). 2014 Apr. (Submitted to *Ophthalmology*).

Schmidt-Erfruth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeiz O, Norenberg C, Sandbrink R, Heier JS (Harinderjit Singh- Participating Clinical Investigator in VIEW studies). Intravitreal aflibercept injection for

neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. *Ophthalmology*. 2014 Jan;121(1):193-201.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). The course of eyes with vitrectomy prior to enrollment in a randomized trial evaluating ranibizumab plus prompt or deferred laser for diabetic macular edema. (Submitted).

Diabetic Retinopathy Clinical Research Network Writing Committee (Harinderjit Singh- Participating Clinical Investigator). Pilot Study of Individuals with Diabetic Macular Edema Undergoing Cataract Surgery. *JAMA Ophthalmol* 2014;132(2):224-6.

Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group (Harinderjit Singh- Participating Clinical Investigator). Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. *Ophthalmology*. 2013 Sep;120(9):184-51.

Jackson TL, FRCOphth, Dugel PU, Bebhuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA; CABERNET Study Group (Harinderjit Singh- Participating Clinical Investigator). Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. *Ophthalmology*. 2013 Aug;120(8):1597-603.

Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Exploratory analysis of the effect of intravitreal Ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol*. 2013 Aug 1;131(8):1033-40.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. *JAMA Ophthalmol*. 2013 Jul;131(7):870-9.

Bhavsar AR, Torres K, Bressler NM, Glassman AR, Jampol LM, Kinyoun JL; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Longer Term Safety Evaluation Following Short Term Use of Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy: 52-Week Results. 2013 Jun. (Submitted to *JAMA Ophthalmology* for publication).

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group (Harinderjit Singh- Participating Clinical Investigator). Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology*. 2013 Oct;120(10):2013-22.

Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group (Harinderjit Singh- Participating Clinical Investigator). Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. *Ophthalmology*. 2013 May;120(5):1046-56.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical

Investigator). Macular edema after cataract surgery in eyes without pre-operative central-involved diabetic macular edema. *JAMA Ophthalmol.* 2013 Apr 18;1-9 (Epub ahead of print).

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol.* 2013 Mar;131(3):283-93.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (Harinderjit Singh- Participating Clinical Investigator in COPERNICUS study). Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. *Am J Ophthalmol.* 2013 Mar;155(3):429-37.

Dugel PU, Bebhuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL; CABERNET Study Group (Harinderjit Singh- Participating Clinical Investigator). Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). *Ophthalmology.* 2013 Feb;120(2):317-27.

Marcus DM, Singh H, Lott MN, Singh J, Marcus MD. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. *Retina.* 2013 Jan;33(1):35-47.

Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J (Harinderjit Singh- Participating Clinical Investigator in MARINA and ANCHOR studies). Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. *Ophthalmology.* 2013 Jan;120(1):160-8.

Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Domalpally A, Doft BH, Elman MJ, Blodi BA; SCORE Study Investigator Group (Harinderjit Singh- Participating Clinical Investigator). Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the Standard Care vs Corticosteroid for REtinal vein occlusion (SCORE) Study: SCORE study report 14. *Arch Ophthalmol.* 2012 Dec;130(12):1517-24.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups (Harinderjit Singh- Participating Clinical Investigator). Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology.* 2012 Dec;119(12):2537-48.

Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, Glassman AR, Grover S, Gupta SK, Nielsen JS; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. *Invest Ophthalmol Vis Sci.* 2012 Dec 13;53(13):8154-61.

Diabetic Retinopathy Clinical Research Network; Elman MH, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, Glassman AR, Maturi RK, Mela M (Harinderjit Singh- Participating Clinical Investigator). Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology.* 2012 Nov;119(11):2312-8.

Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups (Harinderjit Singh- Participating Clinical Investigator). Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. *Ophthalmology*. 2012 Oct;119(10):2108-18.

Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupat A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Bilman K, Kane FE, Green K; FAME Study Group (Harinderjit Singh- Participating Clinical Investigator). Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology*. 2012 Oct;119(10):2125-32.

Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS (Harinderjit Singh- Participating Clinical Investigator in RISE and RIDE studies). Long-term effects of ranibizumab on diabetic retinopathy severity and progression. *Arch Ophthalmol*. 2012 Sep;130(9):1145-52.

Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA; Diabetic Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. *Arch Ophthalmol*. 2012 Sep;130(9):1153-61.

Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group (Harinderjit Singh- Participating Clinical Investigator). Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. *N Engl J Med*. 2012 Aug 16;367(7):606-15.

Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; DA VINCI Study Group (Harinderjit Singh- Participating Clinical Investigator). One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. *Ophthalmology*. 2012 Aug;119(8):1658-65.

Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L (Harinderjit Singh- Participating Clinical Investigator in HORIZON Study). HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology*. 2012 Jun;119(6):1175-83.

Diabetic Retinopathy Clinical Research Network; Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK (Harinderjit Singh- Participating Clinical Investigator). Observational study of subclinical diabetic macular edema. *Eye (Lond)*. 2012 Jun;26(6):833-40.

Bhavsar AR, Stockdale CR, Ferris FL III, Brucker AJ, Bressler NM, Glassman AR; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. *Arch Ophthalmol*. 2012 Jun;130(6):809-10.

Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzback G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA (Harinderjit Singh- Participating Clinical Investigator in COPERNICUS study). Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

Ophthalmology. 2012 May;119(5):1024-32.

Sun JK, Qin H, Aiello LP, Melia M, Beck RW, Andreoli CM, Edwards PA, Flassman AR, Pavlica MR; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh- Participating Clinical Investigator). Evaluation of visual acuity measurements after autorefraction versus manual refraction in eyes with and without diabetic macular edema. *Arch Ophthalmol*. 2012 Apr;130(4):470-9.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group (Harinderjit Singh- Participating Clinical Investigator). Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. *Ophthalmology*. 2012 Apr;119(4):789-801.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (Harinderjit Singh- Participating Clinical Investigator in HORIZON study). Ranibizumab for macular edema due to retinal vein occlusions; long-term follow-up in the HORIZON trial. *Ophthalmology*. 2012 Apr;119(4):802-9.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Glassman AR, Stockdale CR, Beck RW, Baker C, Bressler NM. Evaluation of Masking Study Participants to Intravitreal Injections in a Randomized Clinical Trial. *Arch Ophthalmol*. 2012;130(2):190-194.

Sun JK, Qin H, Aiello LP, Melia M, Beck RW, Andreoli CM, Edwards PA, Flassman AR, Pavlica MR, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Evaluation of visual acuity measurements after Autorefraction versus Manual Refraction in eyes with and without diabetic macular edema. *Arch Ophthalmol*. Dec 2011; EPUB.

Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, Beck RW, Bressler SB, Ferris FL, Glassman AR, Marcus D, Stockdale CR, Diabetic Retinopathy Clinical Research Network Writing Committee (Harinderjit Singh, participating Clinical Investigator). Randomized trial evaluating short-term effects of intravitreal Ranibizumab or Triamcinolone Acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. *Retina*. 2011;31:1009-1027.

Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Expanded 2-Year follow-up of Ranibizumab plus prompt or deferred laser or Triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology*. 2011;118:609-614.

Chan CK, Ip MS, Van Veldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA, SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator). SCORE Study report #11: Incidences of neovascular events in eyes with Retinal Vein Occlusion. *Ophthalmology*. 2011;118:1364-1372.

Scott IU, Van Veldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, Cohen G for the SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator). Baseline predictors of visual acuity and retinal thickness outcomes in patients with Retinal Vein Occlusion: SCORE Study Report 10. *Ophthalmology*. 2011;118:345-352.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Rationale for the Diabetic Retinopathy Clinical Research Network intravitreal Anti-VEGF Treatment and follow-up protocol for center-involved diabetic macular edema. *Ophthalmology*. 2011;118:e5-e14.

Gangaputra S, Almkhatar T, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, for the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Comparison of film and digital Fundus Photographs in eyes of individuals with diabetes mellitus. *IOVS 2011*. Aug 2011;52:6168-73.

Sun JK, Aiello LP, Cavallerano JD, Stockman M, Miller KM, Qin H, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Visual acuity testing using autorefraction or pinhole as compared with manual DRCR protocol refraction in individuals with diabetes. *Ophthalmology*. Mar 2011;118:537-542.

Lauer AK, Bressler NM, Edwards AR, for the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Frequency of intraocular pressure increase within days after intravitreal Triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. *Arch Ophthalmol*. 2011; 129(8):1097-1099.

Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Association of fluorescein angiographic features with visual acuity and with OCT and stereoscopic color fundus photographic features of DME in a randomized clinical trial. *Retina*. Dec 2010; 30(10):1627-37.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (Harinderjit Singh, participating Clinical Investigator). Ranibizumab for macular edema following Central Retinal Vein Occlusion: Six-month primary end point results of a phase III study. *Ophthalmology*. 2010;117:1124-1133.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators (Harinderjit Singh, participating Clinical Investigator). Ranibizumab for macular edema following Branch Retinal Vein Occlusion: Six-month primary end point results of a phase III study. *Ophthalmology*. 2010;117:1102-1112.

Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman A, Ip MS, Miller KM, the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Factors associated with improvement and worsening of visual acuity 2 years after Focal/Grid Photocoagulation for diabetic macular edema. *Ophthalmology*. 2010;117:946-953.

Friberg TR, Tolentino M, LEVEL Study Group (Harinderjit Singh, participating Clinical Investigator). Pegaptanib sodium as maintenance therapy in Neovascular Age-related Macular

Degeneration: The LEVEL study. *Br. J. Ophthalmol.* 2010;94:1611-1617.

Ferris FL, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). A proposed method of logarithmic transformation of ocular coherence tomography data for use in clinical research. *Ophthalmology.* Aug 2010;117:1512–1516.

Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK for the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Randomized trial evaluating Ranibizumab plus prompt or deferred laser or Triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology.* June 2010;117(6):1064-1077.e35.

Blodi BA, Domalpally A, Scott IU, Ip MS, Oden NL, Elledge J, Warren K, Altaweel MM, Kim JE, Vandhuisen PC, SCORE Study Research Group (Harinderjit Singh, participating Clinical Investigator). Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of stereoscopic color Fundus Photographs and Fluorescein Angiograms: SCORE Study Report 9. *Arch. Ophthalmol.* 2010;128:1140-1145.

Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (Harinderjit Singh, participating Clinical Investigator). Randomized controlled trial of an intravitreal Dexamethasone drug delivery system in patients with diabetic macular edema. *Arch. Ophthalmol.* 2010;128:289-296.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG, Sailor Study Research Group (Harinderjit Singh, participating Clinical Investigator). A phase IIIb study to evaluate the safety of Ranibizumab in subjects with Neovascular Age-Related Macular Degeneration. *Ophthalmology.* 2009;116:1731-1739.

Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Effects of dilation on Electronic-ETDRS visual acuity in diabetic patients. *Invest Ophthalmol Vis Sci.* Apr 2009;50(4):1580-4.

Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN and the SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator) . SCORE Study Report 7: Incidence of intravitreal silicone oil droplets associated with Staked-On vs. Luer Cone syringe design. *Am J Ophthalmol.* 2009;148:725-732.

Domalpally A, Blodi BA, Scott IU, Ip MS, Oden NL, Lauer AK, Van Veldhuisen PC and the SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator). The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of Optical Coherence Tomograms: SCORE Study Report 4. *Arch Ophthalmol.* 2009;127(11):1461-1467.

Ip MS, Oden NL, Scott IU, Van Veldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator).

SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology*. 2009;116:1770-1777.

Scott IU, Blodi BA, Ip MS, VanVeldhuisen PC, Oden NL, Chan CK, Gonzalez V, the SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator). SCORE Study Report 2: Inter-observer agreement between investigator and Reading Center Classification of Retinal Vein Occlusion type. *Ophthalmology*. 2009;116:756-761.

Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. *Arch Ophthalmol*. Dec 2009;127(12):1566-71.

Gardner TW, Larsen M, Girach A, Zhi X, Protein Kinase C Diabetic Retinopathy Study Group (PKC-DRS2) (Harinderjit Singh, participating Clinical Investigator). Diabetic macular edema and visual loss: Relationship to location, severity and duration. *ACTA Ophthalmol*. 2009;87:709-713.

The SCORE Study Research Group (Harinderjit Singh, participating Clinical Investigator). A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol*. Sep 2009;127(9):1115-28.

The SCORE Study Research Group (Harinderjit Singh, participating Clinical Investigator). A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol*. Sep 2009;127(9):1101-14.

Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L, PKC-DRS2 Study Group (Harinderjit Singh, participating Clinical Investigator). Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy. *Eye*. 2009;23:209-214.

Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Haujing Q for the Diabetic Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Effect of Focal/Grid Photocoagulation on visual acuity and retinal thickening in eyes with non-centered involved macular edema. *Retina*. 2009;29:613-617.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Three year follow-up of a randomized trial comparing Focal Grid Photocoagulation and Intravitreal Triamcinolone for diabetic macular edema. *Arch Ophthalmol*. 2009;127:245-251.

Scott IU, Van Veldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, SCORE Study Investigator Group (Harinderjit Singh, participating Clinical Investigator). SCORE Study Report 1: Baseline associations between central retinal thickness and visual acuity in patients with Retinal

Vein Occlusion. *Ophthalmology*. Mar 2009;116(3):504-12.

Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignatic L, PKC-DRS2 Study Group (Harinderjit Singh, participating Clinical Investigator). Effect of Ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. *Invest. Ophthalmol. Vis. Sci.* 2009;50:1-4.

Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C, Diabetic Research Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Comparison of Optical Coherence Tomography in diabetic macular edema, with and without Reading Center Manual grading from a clinical trials perspective. *Investig. Ophthalmol. Vis. Sci.* 2009;50:506-511.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Observational study of the development of diabetic macular edema following Panretinal (Scatter) Photocoagulation given in 1 or 4 sittings. *Arch. Ophthalmol.* 2009;127:132-140.

Bhavsar AR, Bressler NM, Brucker AJ, Elman MJ, Googe AR, Joseph M, Stockdale R; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials. *Arch. Ophthalmol.* 2009;127:1581-1583.

Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Association of the extent of diabetic macular edema as assessed by Optical Coherence Tomography with visual acuity and retinal outcome variables. *Retina*. Mar 2009;29(3):300-5.

Browning DJ, Miller KM, Aiello LP, Beck RW, Bressler NM, Davis MD, DiLoreto DA, Ferris FL, Friedman SM, Glassman AR, Glazer LC, Kollman C, Lauer Ak, Marcus DM, Starr J, the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). The course of response to Focal/Grid Photocoagulation for diabetic macular edema. *Retina*. 2009;29:1436-1443.

Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features. *Retina*. Jul-Aug 2008;28(7):919-30.

Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H for the Diabetic Retinopathy Clinical Trial Research Network (Harinderjit Singh, participating Clinical Investigator). Optical coherence tomography measurements and analysis methods in optical coherence studies of diabetic macular edema. *Ophthalmology*. 2008;115:1366-1371.

Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DB, Flaxel CJ, Fong DS, Foster WJ,

Glassman AR, Hartnett ER, Kollman C, Li HK, Haijing Q, Scott IU, and the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Comparison of time-domain OCT and Fundus Photographic assessments of retinal thickening in eyes with diabetic macular edema. *Investigat. Ophthalmol. Vis. Sci.* 2008;49:1745-1752.

Lott MN, Manning MH, Singh J, Zhang H, Singh H, Marcus DM. 23-Gauge vitrectomy in 100 eyes: short-term visual outcomes and complications. *Retina.* 2008 Oct;28(9):1193-200.

Lott MN, Fuller JJ, Hancock HA, Singh J, Singh H, McGwin G, Marcus DM. Vitreal penetration of oral moxifloxacin in humans. *Retina.* 2008 Mar;28(3):473-6.

Ip MS, Edwards AR, Beck RW, Bressler NM, Aiello LP, Browning DJ, Elman MJ, Friedman SM, Ferris FL, Glassman AR, Kollman C, Price A (Harinderjit Singh, participating Clinical Investigator). A randomized trial comparing intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for diabetic macular edema. *Ophthalmol.* 2008;115:1447-1449.e1-10.

Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Diabetic macular edema: What is focal and what is diffuse?. *Am J Ophthalmol.* Nov 2008;146(5):649-55.e1-6.

Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). A phase II randomized clinical trial of intravitreal Bevacizumab for diabetic macular edema. *Ophthalmology.* Oct 2007;114(10):1860-7.

Bhavsar AR, Ip MS, Glassman AR; DRCR.net and the SCORE Study Groups (Harinderjit Singh, participating Clinical Investigator). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE Clinical Trials. *Am J Ophthalmol.* Sep 2007;144(3): 454-6.

Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. *Am J Ophthalmol.* May 2008;145(5):894-901.

Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H, and the Diabetic Retinopathy Clinical Research Network Study Group (Harinderjit Singh, participating Clinical Investigator). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal Bevacizumab for diabetic macular edema. *Retina.* Jan 2008;28(1):36-40.

Fuller J, Lott MN, Bhaati AA, Henson NM, Curtis MA, Singh HJ, Marcus DM. Vitreal penetration of oral and topical moxifloxacin in humans. *Am J Ophthalmol.* 2007 Feb;143(2):338-40.

Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). A phase 2 randomized clinical trial of intravitreal Bevacizumab for diabetic macular edema. *Ophthalmology*, Oct 2007;114(10):1860-7.

Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD, and the Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol*. Apr 2007;125(4):469-80.

Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JJ, Miskala PH, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology*. Mar 2007;114(3):525-36.

Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C; Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*. Aug 2007;114(8):1520-5.

PKC-DRS2 Study Group (Harinderjit Singh, participating Clinical Investigator). The effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. *Ophthalmology*. 2006;113:2221-2230.

Macugen Diabetic Retinopathy Study Group. (Harinderjit Singh, participating Clinical Investigator). Changes in Retinal Neovascularization after Pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology*. 2006;113:23-28.

Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd, Diabetic Retinopathy Clinical Research Network (Harinderjit Singh, participating Clinical Investigator). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol*. Dec 2006;124(12):1701-7.

Macugen Diabetic Retinopathy Study Group. (Harinderjit Singh, participating Clinical Investigator). A phase II randomized double-masked trial of Pegaptanib, an anti-Vascular Endothelial Growth Factor Aptamer, for diabetic macular edema. *Ophthalmology*. 2005;112:1747-1757.

Liou GI, Samuel S, Matroogan S, Goss KH, Santoro I, Groden J, Hunt RC, Wang F, Miller SS, Caldwell RB, Rustgi AK, Singh H, Marcus DM. Alternative splicing of the APC gene in the neural retina and retinal pigment epithelium. *Mol. Vision*. 2004;10:383-391.

Bains H, Patel M, Singh H, Marcus DM. Surgical excision of Peripapillary Choroidal Neovascular Membranes in the elderly. *Retina*. 2003;23:469-474.

Singh H. Discussion of the evaluation and management of macular holes. *Focal Points*. Mar 2003;21(1).

Singh H, Grand, MG. Treatment of blood induced glaucoma by Trans Pars Plana Vitrectomy. *Retina*. 1981;1(3):255-257.

Stiller CR, Sinclair NR, Abrahams S, McGirr D, Singh H, Howson WT, Ulan RA. Anti-Donor immune response in prediction of transplant rejection. *N Eng J Med*. 1976;294:978-982.

PUBLICATIONS IN NON-REFERRED JOURNALS

Humoral and Cellular Presensitization in Transplantation: (unpublished data)

CHARITABLE CONTRIBUTIONS

- 2011- Present Guru Granth Sahib Sikh Society, Chandigarh, India
- * Attended Eye Camp in Chandigarh, India, seeing patients for consultation, February, 2011 to present . Visiting twice a year.
 - * Attended Eye Camp in Nanded, Maharashtra, seeing patients for consultation, performing surgery, injections, and laser for vitreoretinal and other ophthalmologic issues, and assessing patients for cataract surgeries. In this eye camp 150 Cataract surgeries were performed. From December 18- December 22, 2011
- 2008- Present Grewal Eye Institute, Chandigarh, India
- * Visiting physician twice a year for consultation and vitreoretinal surgeries
- 2006 Jabalpur, Madhya Pradesh, India
- * Attended Eye Camp organized by the Lion's Club for two days. Performed eye exams and patients who needed vitreoretinal surgery were operated on in Chandigarh, India
- 1998 Al-Shifa Trust Eye Hospital, Rawalpindi Pakistan
- * Examined patients in consultation and examined for vitreoretinal diseases
- 1994- Present Guru Harkrishan Charitable Eye Hospital, Sohana Near Chandigarh, India.
- * Initial promoting member of hospital
 - * Served as Trustee of the organization and was instrumental in designing the facility. Also supplied equipment worth millions of dollars to this charitable organization during this time period

- * Visited twice a year for 10 to 14 days to work in the hospital by examining patients, consulting and performing vitreoretinal surgeries

1994, 1997 Tribhuvan University Teaching Hospital, Kathmandu, Nepal

- * Participated in Eye Camps, seeing pts and performing Vitreo retina surgeries.